Details about Jeffrey Hoch

Access statistics for papers by Jeffrey Hoch.

Last updated 2023-05-13. Update your information in the RePEc Author Service.

Short-id: pho785

Journal Articles

2019

1. A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis
   PharmacoEconomics, 2019, 37, (12), 1525-1536

2018

2. Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom
   PharmacoEconomics - Open, 2018, 2, (3), 225-231
3. Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment
   PharmacoEconomics, 2018, 36, (1), 7-15 View citations (1)
4. The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study
   PharmacoEconomics - Open, 2018, 2, (3), 255-270

2017

5. Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
   PharmacoEconomics - Open, 2017, 1, (3), 167-173
6. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening
   PLOS ONE, 2017, 12, (3), 1-15 View citations (1)
7. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
   PharmacoEconomics - Open, 2017, 1, (4), 255-263

2016

8. Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors
   PLOS ONE, 2016, 11, (4), 1-13 View citations (1)
9. Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation
   Applied Health Economics and Health Policy, 2016, 14, (3), 313-322

2015

10. Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters
    PharmacoEconomics, 2015, 33, (10), 1083-1090 View citations (1)
11. Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
    PharmacoEconomics, 2015, 33, (8), 879-882

2014

12. A Review and Meta-analysis of Colorectal Cancer Utilities
    Medical Decision Making, 2014, 34, (6), 809-818 View citations (5)
13. Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control
    Social Science & Medicine, 2014, 122, (C), 130-139 View citations (2)

2013

14. The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada
    PharmacoEconomics, 2013, 31, (3), 229-236 View citations (3)

2008

15. Measuring and illustrating statistical evidence in a cost-effectiveness analysis
    Journal of Health Economics, 2008, 27, (2), 476-495 View citations (3)

2007

16. Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions
    PharmacoEconomics, 2007, 25, (10), 807-816 View citations (3)

2004

17. Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data
    Health Economics, 2004, 13, (5), 461-475 View citations (36)

2002

18. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis
    Health Economics, 2002, 11, (5), 415-430 View citations (74)

Chapters

2021

1. Labs and cases in health insurance and cost-effectiveness analyses to enhance active learning experiences in an introductory healtheconomics course for students in health professions
   Chapter 4 in Handbook on Teaching Health Economics, 2021, pp 44-60
2. Using net benefit regression to teach cost-effectiveness analysis with a dataset
   Chapter 6 in Handbook on Teaching Health Economics, 2021, pp 77-87

2018

3. Econometric Considerations When Using the Net Benefit Regression Framework to Conduct Cost-effectiveness Analysis
   A chapter in Health Econometrics, 2018, vol. 294, pp 119-143

2013

4. Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario
   Springer